These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38529286)

  • 1. Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas.
    Song D; Yang Q; Li L; Wei Y; Zhang C; Du H; Ren G; Li H
    Front Immunol; 2024; 15():1372113. PubMed ID: 38529286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
    Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
    Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
    Li J; Zhang Y; Qu Z; Ding R; Yin X
    Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
    Liu J; Xu K; Ma L; Wang Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
    Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
    Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
    Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
    Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TBC1D1 represses glioma progression by altering the integrity of the cytoskeleton.
    Cai J; Jiang Y; Chen P; Liang J; Zhang Y; Yuan R; Fan H; Zhong Y; Cai J; Cheng S; Zhang Y
    Aging (Albany NY); 2024 Jan; 16(1):431-444. PubMed ID: 38189823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Qu S; Liu J; Wang H
    Front Immunol; 2021; 12():648416. PubMed ID: 33889156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas.
    He G; Chen Z; Zhuo S; Tang J; Hao W; Yang K; Yang C
    Hum Cell; 2022 Nov; 35(6):1976-1992. PubMed ID: 36129672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
    Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
    Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
    [No Abstract]   [Full Text] [Related]  

  • 14.
    Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
    J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M2 macrophage marker CHI3L2 could serve as a potential prognostic and immunological biomarker in glioma by integrated single-cell and bulk RNA-Seq analysis.
    Qian W; Wang Q; Zhang C; Zhu J; Zhang Q; Luo C
    J Gene Med; 2023 Sep; 25(9):e3523. PubMed ID: 37147894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.
    Jiang Y; Ji Q; Long X; Wang P; Tu Z; Zhang X; Zhu X; Huang K; Li J
    Front Immunol; 2022; 13():810832. PubMed ID: 35265072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
    Hu Y; Tu Z; Lei K; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
    Wang Y; Zhao W; Liu X; Guan G; Zhuang M
    J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.